Neoantigens Market Size, Trends and Growth Analysis by 2027

The global market for neoantigens is projected to grow significantly, reaching approximately US$ 1,054,783.54 thousand by 2028, up from US$ 271,428.57 thousand in 2023. This growth represents a remarkable compound annual growth rate (CAGR) of 31.2% from 2023 to 2028.

Cancer has become a predominant cause of mortality across the globe. The World Health Organization (WHO) reported that in 2019, cancer was the leading cause of death for individuals under 70 years old in 183 countries, and it ranked as the fourth leading cause of death in 123 countries. Furthermore, data released by the WHO in March 2021 indicated that approximately 10 million deaths were attributed to various forms of cancer in 2020. Below is a summary of new cancer cases recorded in 2020:

Source: WHO's cancer data for 2020

The rising incidence of cancer has placed immense pressure on healthcare systems globally. The International Agency for Research on Cancer (IARC) estimates that the number of new cancer cases worldwide could reach around 27.5 million by 2040, with the disease potentially causing approximately 163 million deaths by that time. Contributing factors include lifestyle changes, tobacco use, decreased physical activity, and fluctuating health and environmental conditions, which are expected to exacerbate the cancer burden in the future. Therefore, it is crucial to implement effective strategies for cancer prevention and control.

In response to the growing cancer crisis, various governments have launched initiatives aimed at enhancing treatment and preventive measures. For example, in 2017, the World Health Assembly adopted the Resolution on Cancer (WHA70.12), which promotes a comprehensive approach to cancer prevention and control. This initiative encourages the WHO and national governments to intensify their efforts to meet the objectives outlined in the Global Action Plan (2013-2020) for the prevention and control of noncommunicable diseases (NCDs) and the 2030 UN Agenda for Sustainable Development aimed at reducing premature cancer deaths. Additionally, numerous private organizations have joined these efforts, further driving the demand for improved preventive strategies against cancer. Consequently, the increasing cancer prevalence has spurred interest in innovative therapeutic solutions such as neoantigens, thereby propelling market growth.

The neoantigens market is categorized based on treatment types into combination therapy and monotherapy. As of 2023, the combination therapy segment is anticipated to dominate the market share, while the monotherapy segment is projected to experience more rapid growth throughout the forecast period.

Furthermore, the market is segmented by therapeutic specialty, including gastrointestinal cancer, lung cancer, solid tumors, urinary system cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is expected to capture the largest market share and is also forecasted to grow at the fastest rate in the upcoming years.

Key sources consulted in the preparation of the report on the neoantigens market include the American Association for Cancer Research, Cancer Association of South Africa, European Medicines Agency, Food and Drug Administration, Institute for Research in Immunology and Cancer - Commercialization of Research, and the World Health Organization, among others.